IGF-1 LR3 for muscle growth: what the evidence actually shows

What did @j.lifts33 actually say?

The creator described an eight-week personal run of IGF-1 LR3, reporting exceptional muscle pumps that outlasted the cycle by six weeks. They admitted to initially taking it before bed, called that a mistake, and corrected course to post-workout dosing. They also put a ceiling on realistic gains, saying "you can build 10 to 15 pounds if you're locked in" but not 30 to 40 pounds.

To their credit, they explicitly said this is not medical advice and framed everything as personal experience. That disclaimer matters because IGF-1 LR3 is not FDA-approved for human use, is not available through licensed pharmacies for bodybuilding purposes, and carries a real risk profile that a 42,000-view TikTok video can't adequately cover in 45 seconds.

Does the science back this up?

Partially, but with significant caveats. The post-workout timing logic has a biological basis, but the 10-to-15-pound gain claim is not well-supported by controlled human research. Most of what we know about IGF-1 LR3 comes from animal studies and a limited number of clinical trials in specific disease populations.

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1, modified to resist IGF-binding proteins and extend its half-life from minutes to roughly 20-30 hours (Tomas et al., 1993, Journal of Endocrinology). That extended activity is the entire reason it's interesting to athletes. In animal models, it produces significant skeletal muscle hypertrophy. In humans, clinical IGF-1 research has focused on growth deficiencies and ALS, not healthy athletes packing on lean mass. The clean 10-to-15-pound lean mass figure has no controlled trial behind it in healthy adults. It is gym lore, not literature.

What did they get wrong (or right)?

The post-workout timing rationale deserves some credit, but the explanation is imprecise. The gain ceiling they cited is speculative, and the word "immaculate" applied to pumps is anecdote, not evidence.

On timing: the creator's reasoning, that post-workout blood flow and insulin sensitivity are elevated, is directionally correct. Exercise transiently increases glucose uptake and muscle blood flow, which could theoretically improve peptide delivery to target tissue. However, given IGF-1 LR3's half-life of 20-30 hours, the pharmacokinetic argument for precise post-workout timing is weaker than it would be for a short-acting compound. The timing preference likely matters less than they implied.

On the gain claim: saying you "can build 10 to 15 pounds" is presented with more confidence than the evidence warrants. No peer-reviewed trial in healthy resistance-trained humans has established that number. It may be lower. It may come with water retention mixed in. Presenting it as a reliable ceiling misleads viewers into treating anecdote as clinical data.

What they got right: correctly distinguishing IGF-1 LR3 from anabolic steroids ("not gear") is accurate and actually useful framing for an audience that may not know the difference.

What should you actually know?

IGF-1 LR3 is not a regulated therapeutic agent for bodybuilding. It is not cleared for this use by any major regulatory body, and using it outside a supervised clinical context carries risks that go well beyond "immaculate pumps."

The safety concerns are real. IGF-1 signaling is involved in cell proliferation broadly, not just in muscle. Elevated IGF-1 has been associated with increased risk of certain cancers in epidemiological studies (Renehan et al., 2004, Lancet). That does not mean a short cycle causes cancer, but it means the risk-benefit math in a healthy person is not trivial. Additionally, IGF-1 LR3 has insulin-like activity, which introduces hypoglycemia risk, particularly relevant given the creator's original mistake of taking it before bed without food. There is also no long-term safety data in healthy athletes because those trials have not been done.

If you are interested in peptide therapy for recovery or body composition through a legitimate channel, the conversation starts with a licensed provider reviewing your labs, not a TikTok comment section.